Hormone replacement therapy and cardiovascular disease: Does route of administration and formulation matter? [1]

British Journal of Haematology

Volumn 124, Issue 6, 2004, Pages 836-840

  Foster, William ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Atherosclerosis; Coronary heart disease; Hormone replacement therapy; Oestrogen; Vascular function

Indexed keywords

BIOCHEMICAL MARKER; BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; ESTRADIOL; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; NORETHISTERONE ACETATE; SOMATOMEDIN C; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FORMULATION; ESTROGEN THERAPY; FOLLOW UP; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LETTER; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT; STROKE; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; WELLBEING;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS;

EID: 1642308587     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.04847.x     Document Type: Letter

References (37)

1. van Baal, W.M., Kenemans, P., Emeis, J.J., Schalkwijk, C.G., Mijatovic, V., van der Mooren, M.J., Vischer, U.M. & Stehouwer, C.D. (1999) Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertility and Sterility, 71, 663-670.
2. Beral, V., Banks, E. & Reeves, G. (2002) Evidence from randomized trials on the long-term effects of hormone replacement therapy. Lancet, 360, 942-944.
3. Cagnacci, A., Tarquini, R., Perfetto, F., Aragino, S., Zanni, A.L., Cagnacci, P., Facchinetti, F. & Volpe, A. (2003) Endothelin-1 and nitric oxide levels are related to cardiovascular risk factors but are not modified by estradiol replacement in healthy postmenopausal women. A cross-sectional and a randomised cross-over study. Maturitas, 44, 117-124.
4. Caine, Y.G., Bauer, K.A. & Barzegar, S. (1992) Coagulation activation following estrogen administration in postmenopausal women. Thrombosis and Haemostasis, 68, 392-395.
5. Chong, A.-Y., Blann, A.D. & Lip, G.Y.H. (2003) Assessment of endothelial damage and dysfunction: observations in relation to heart failure. Quarterly Journal of Medicine, 96, 253-267.
6. Cushman, M., Legault, C., Barrett-Connor, E., Stefanick, M.L., Kessler, C., Judd, H.L., Sakkinen, P.A., Tracy, R.P. (1999) Effect of postmenopausal hormones on inflammation-sensitive proteins: the postmenopausal estrogen/progestin interventions (PEPI) study. Circulation, 100, 717-722.
7. Daly, E., Vessey, M.P., Hawkins, M.M., Carson, J.L., Gough, P. & Marsh, S. (1996) Risk of venous thromboembolism in users of hormone replacement therapy. Lancet, 348, 977-980.
8. Edmunds, E. & Lip, G.Y.H. (2000) Cardiovascular risk in women: the cardiologist's perspective. Quarterly Journal of Medicine, 93, 135-145.
9. Grady, D., Rubin, S.M., Petitti, D.B., Fox, C.S., Black, D., Ettinger, B., Ernster, V.L. & Cummings, S.R. (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of Internal Medicine, 117, 1016-1037.
10. Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., Hulley, S., Herd, A., Khan, S., Newby, L.K., Waters, D., Vittinghoff, E. & Wenger, N.HERS Research Group. (2002) Cardiovascular outcomes during 6.8 years of hormone therapy. Journal of the American Medical Association, 288, 49-57.
11. Humphrey, L.L., Chan, B.K. & Sox, H.C. (2002) Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Annals of Internal Medicine, 137, 273-284.
12. Hwang, S.J., Ballantyne, C.M., Sharrett, A.R., Smith, L.C., Davis, C.E., Gotto, A.M. Jr & Boerwinkle, E. (1997) Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the atherosclerosis risk in communities (ARIC) study. Circulation, 96, 4219-4225.
13. Kai, H., Ikeda, H., Yasukawa, H., Kai, M., Seid, Y., Kuwahara, F., Ueno, T., Sugi, K., Imaizumi T. (1998) Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. Journal of the American College of Cardiology, 32, 368-372.
14. Lee, K.W., Freestone, B., Harris, L. & Lip, G.Y. (2002) HRT in a general practice population: further observations on the 'healthy cohort' effect. International Journal of Clinical Practice, 56, 486-487.
15. Lieberman, E.H., Gerhard, M.D., Uehata, A., Walsh, B.W., Selwyn, A.P, Ganz, P., Yeung, A.C. & Creager, M.A. (1994) Estrogen improves endothelial-dependent flow-mediated vasodilation in postmenopausal women. Annals of Internal Medicine, 121, 936-941.
16. Lip, G.Y.H. & Felmeden, D.C. (2001) Hormone replacement therapy and cardiovascular risk: do abnormalities of coagulation and fibrinolysis matter? Journal of Internal Medicine, 249, 201-204.
17. Lip, G.Y., Blann, A.D., Jones, A.F. & Beevers, D.G. (1997) Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. American Heart Journal, 134, 764-771.
18. Lydakis, C., Kerr, H., Hutchings, K. & Lip, G.Y. (1998) Women's awareness of, and attitudes towards, hormone replacement therapy: ethnic differences and effects of age and education. International Journal of Clinical Practice, 52, 7-12.
19. Manson, J.E., Hsia, J., Johnson, K.C., Rossouw, J.E., Assaf, A.R., Lasser, N.L., Trevisan, M., Black, H.R., Heckbert, S.R., Detrano, R., Strickland, O.L., Wong, N.D., Crouse, J.R., Stein, E. & Cushman, M., for the Women's Health Initiative Investigators. (2003) Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine, 349, 523-534.
20. Rabbani, L.E., Seminario, N.A., Sciacca, R.R., Chen, H.J. & Giardina, E.G. (2002) Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women. Journal of the American College of Cardiology, 40, 1991-1999.
21. Roldan, V., Marin, F., Lip, G.Y. & Blann, A.D. (2003) Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thrombosis and Haemostasis, 90, 1007-1020
22. Sanada, M., Higashi, Y., Nakagawa, K., Sasaki, S., Kodama, I., Sakashita, T., Tsuda, M. & Ohama, K. (2001) Estrogen replacement therapy in postmenopausal women augments reactive hyperemia in the forearm by reducing angiotensin converting enzyme activity. Atherosclerosis, 158, 391-397.
23. Scarabin, P.Y., Alhenc-Gelas, M., Plu-Bureau, G., Taisne, P., Agher, R. & Aiach, M. (1997) Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arteriosclerosis, Thrombosis and Vascular Biology, 17, 3071-3078.
24. Scarabin, P.-Y., Oger, E. & Plu-Bureau, G., ESTHER study group. (2003) Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet, 362, 428-132.
25. Seljeflot, I., Arnesen, H., Hofstad, A.E. & Os, I. (2000) Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease. Thrombosis and Haemostasis, 83, 944-948.
26. Shi, Y., Patel, S., Niculescu, R., Chung, W., Desrochers, P. & Zalewsk, A. (1999) Role of matrix metalloproteinases and their tissue inhibitors in the regulation of coronary cell migration. Arteriosclerosis, Thrombosis and Vascular Biology, 19, 1150-1155.
27. Silvestri, A., Gebara, O., Vitale, C., Wajngarten, M., Leonardo, F., Ramires, J.A., Fini, M., Mercuro, G. & Rosano, G.M. (2003) Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation, 107, 3165-3169.
28. Stevenson, J.C., Oladipo, A., Manassiev, N., Whitehead, M.I., Guilford, S. & Proudler, A. (2004) Randomized trial of effect of transdermal continuous combined HRT on cardiovascular risk markers. British Journal of Haematology, 124, 802-808.
29. Stojanovic, N.D., Kwong, P., Byrne, D.J., Arnold, A., Jagroop, I.A., Nair, D., Press, M., Hurel, S., Mikhailidis, D.P. & Prelevic, G.M. (2003) The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study. Angiology, 54, 391-399.
30. Stork, S., von Schacky, C. & Angerer P. (2002) The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis, 165, 301-307.
31. Strandberg, T.E., Ylikorkala, O. & Tikkanen, M.J. (2003) Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women. American Journal of Cardiology, 92, 212-214.
32. Tayebjee, M.H., MacFadyen, R.J. & Lip, G.Y. (2003) Extracellular matrix biology: a new frontier in linking the pathology and therapy of hypertension? Journal of Hypertension, 21, 2211-2218.
33. The Writing Group for the PEPI Trial. (1995) Effects of oestrogen or oestrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Journal of the American Medical Association, 273, 199-208.
34. Vehkavaara, S., Hakala-Ala-Pietila, T., Virkamaki, A., Bergholm, R., Ehnholm, C., Hovatta, O., Taskinen, M.R. & Yki-Jarvinen, H. (2000) Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation, 102, 2687-2693.
35. Vongpatanasin, W., Tuncel, M., Wang, Z., Arbique, D., Mehrad, B. & Jialal I. (2003) Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. Journal of the American College of Cardiology, 41, 1358-1363.
36. Wassertheil-Smoller, S., Hendrix, S.L., Limacher, M., Heiss, G., Kooperberg, C., Baird, A., Kotchen, T., Curb, J.D., Black, H., Rossouw, J.E., Aragaki, A., Safford, M., Stein, E., Laowattana, S. & Mysiw, W.J., for the WHI investigators. (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomised trial. Journal of the American Medical Association, 289, 2673-2684.
37. Zanger, D., Yang, B.K., Ardans, J., Waclawiw, M.A., Csako, G., Wahl, L.M. & Cannon, R.O.3rd (2000) Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. Journal of the American College of Cardiology, 36, 1797-1802.